The released PTX exerts chemotherapy on NSCLC cells as well as immunogenic cell death induction, while GDC0919 promotes the immuno‐chemotherapeutic effect of PTX through IDO inhibition. This evidence concerns the gene IDO1 and non-small cell lung carcinoma.